Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Sorafenib can cause rare skin reactions, but treatment can continue with additional care.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

Gefitinib can cause hair and eyebrow darkening.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Blocking mTORC1 reduces skin tumor growth in mice.

Ritlecitinib was generally well tolerated in children with alopecia areata.

A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.

Upadacitinib effectively treated severe hair loss in a child.

Sorafenib can cause a temporary skin condition that goes away after stopping the drug.

Afatinib often causes skin problems that need proactive management.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Upadacitinib may effectively treat alopecia areata without side effects.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.